This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2019 Apr 25;380(17):1678.

doi: 10.1056/NEJMc1902165.

Cardiovascular Risk Reduction with Icosapent Ethyl. Reply

Deepak L Bhatt¹, P Gabriel Steg², Michael Miller³

Affiliations

Affiliations

¹ Brigham and Women's Hospital, Boston, MA dlbhattmd@post.harvard.edu.
² Assistance Publique-Hôpitaux de Paris, Paris, France.
³ University of Maryland School of Medicine, Baltimore, MD.

PMID: 31018077
DOI: 10.1056/NEJMc1902165

Comment

Cardiovascular Risk Reduction with Icosapent Ethyl. Reply

Deepak L Bhatt et al. N Engl J Med. 2019.

. 2019 Apr 25;380(17):1678.

doi: 10.1056/NEJMc1902165.

Authors

Deepak L Bhatt¹, P Gabriel Steg², Michael Miller³

Affiliations

¹ Brigham and Women's Hospital, Boston, MA dlbhattmd@post.harvard.edu.
² Assistance Publique-Hôpitaux de Paris, Paris, France.
³ University of Maryland School of Medicine, Baltimore, MD.

PMID: 31018077
DOI: 10.1056/NEJMc1902165

No abstract available

PubMed Disclaimer

Comment in

Novel antibody-based reversal agent for ticagrelor.
Huynh K. Huynh K. Nat Rev Cardiol. 2019 Jun;16(6):320-321. doi: 10.1038/s41569-019-0191-4. Nat Rev Cardiol. 2019. PMID: 30926907 No abstract available.

Comment on

Cardiovascular Risk Reduction with Icosapent Ethyl.
Chan LN. Chan LN. N Engl J Med. 2019 Apr 25;380(17):1677. doi: 10.1056/NEJMc1902165. N Engl J Med. 2019. PMID: 31018075 No abstract available.
Cardiovascular Risk Reduction with Icosapent Ethyl.
Borghi C, Fogacci F, Cicero AFG. Borghi C, et al. N Engl J Med. 2019 Apr 25;380(17):1678. doi: 10.1056/NEJMc1902165. N Engl J Med. 2019. PMID: 31018076 No abstract available.

Similar articles

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Bhatt DL, et al. N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10. N Engl J Med. 2019. PMID: 30415628 Clinical Trial.
Cardiovascular Risk Reduction with Icosapent Ethyl.
Borghi C, Fogacci F, Cicero AFG. Borghi C, et al. N Engl J Med. 2019 Apr 25;380(17):1678. doi: 10.1056/NEJMc1902165. N Engl J Med. 2019. PMID: 31018076 No abstract available.
Cardiovascular Risk Reduction with Icosapent Ethyl.
Chan LN. Chan LN. N Engl J Med. 2019 Apr 25;380(17):1677. doi: 10.1056/NEJMc1902165. N Engl J Med. 2019. PMID: 31018075 No abstract available.
Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
Chapman MJ, Zamorano JL, Parhofer KG. Chapman MJ, et al. Pharmacol Ther. 2022 Sep;237:108172. doi: 10.1016/j.pharmthera.2022.108172. Epub 2022 Mar 15. Pharmacol Ther. 2022. PMID: 35304222 Review.
The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
Trivedi K, Le V, Nelson JR. Trivedi K, et al. Postgrad Med. 2021 Jan;133(1):28-41. doi: 10.1080/00325481.2020.1783937. Epub 2020 Aug 6. Postgrad Med. 2021. PMID: 32762268 Review.

See all similar articles

Cited by

Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid.
Mason RP, Libby P, Bhatt DL. Mason RP, et al. Arterioscler Thromb Vasc Biol. 2020 May;40(5):1135-1147. doi: 10.1161/ATVBAHA.119.313286. Epub 2020 Mar 26. Arterioscler Thromb Vasc Biol. 2020. PMID: 32212849 Free PMC article. Review.
EPA and DHA containing phospholipids have contrasting effects on membrane structure.
Sherratt SCR, Juliano RA, Copland C, Bhatt DL, Libby P, Mason RP. Sherratt SCR, et al. J Lipid Res. 2021;62:100106. doi: 10.1016/j.jlr.2021.100106. Epub 2021 Aug 13. J Lipid Res. 2021. PMID: 34400132 Free PMC article.
E-series resolvin metabolome, biosynthesis and critical role of stereochemistry of specialized pro-resolving mediators (SPMs) in inflammation-resolution: Preparing SPMs for long COVID-19, human clinical trials, and targeted precision nutrition.
Serhan CN, Libreros S, Nshimiyimana R. Serhan CN, et al. Semin Immunol. 2022 Jan;59:101597. doi: 10.1016/j.smim.2022.101597. Epub 2022 Feb 16. Semin Immunol. 2022. PMID: 35227568 Free PMC article. Review.
Lipid Disorders Management Strategies (2024) in Prediabetic and Diabetic Patients.
Gaita L, Timar B, Timar R, Fras Z, Gaita D, Banach M. Gaita L, et al. Pharmaceuticals (Basel). 2024 Feb 7;17(2):219. doi: 10.3390/ph17020219. Pharmaceuticals (Basel). 2024. PMID: 38399434 Free PMC article. Review.
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States.
Bhatt DL, Miller M, Brinton EA, Jacobson TA, Steg PG, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Olshansky B, Chung MK, Gibson CM, Giugliano RP, Budoff MJ, Ballantyne CM; REDUCE-IT Investigators. Bhatt DL, et al. Circulation. 2020 Feb 4;141(5):367-375. doi: 10.1161/CIRCULATIONAHA.119.044440. Epub 2019 Nov 11. Circulation. 2020. PMID: 31707829 Free PMC article. Clinical Trial.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information